Translate the text from Welsh to English.



 
Daw hyn yn sgil adolygiad gan y Comisiwn Meddyginiaethau Dynol (CHM) a’r Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA).  

  

Cafodd y gwaharddiad ei gyflwyno yn y DU yn 1999 mewn ymateb i epidemig amrywiolyn Creutzfeld–Jakob (vCJD), y credir iddo fod yn gysylltiedig â bwyta cynhyrchion cig wedi’u heintio â BSE, sef “clefyd y gwartheg gwallgof”.  

  

Ers cyflwyno’r gwaharddiad, mae cynhyrchion meddyginiaethol sy’n deillio o blasma wedi gorfod cael eu mewnforio, yn bennaf o’r Unol Daleithiau ar hyn o bryd.


Dywedodd y Gweinidog Iechyd Vaughan Gething:



> "Mae’r angen i fewnforio plasma i’r DU wedi golygu bod GIG Cymru wedi gorfod blaenoriaethu cyflenwi meddyginiaethau i gleifion â’r angen clinigol mwyaf.  
> 
> “Mae’r pandemig yn rhoi rhagor o bwysau ar y cyflenwad hwnnw oherwydd yr angen cynyddol am blasma gwaed i ddatblygu meddyginiaethau Covid\-19 newydd ynghyd â’r gostyngiad mewn rhoddion plasma gwaed.  
> 
>   
> 
> “Yn dilyn sawl adolygiad o’r dystiolaeth, rydym wedi cael ein cynghori bod plasma o’r DU yn ddiogel i gynhyrchu’r meddyginiaethau hyn ac felly rwyf i, ynghyd â’r gweinidogion iechyd eraill yn y DU, wedi codi’r gwaharddiad. Mae gan hyn y potensial i achub bywydau a bydd yn helpu pobl i reoli eu cyflyrau.”


Dywedodd Cyfarwyddwr Gwasanaeth Gwaed Cymru, Alan Prosser:



> “Mae Gwasanaeth Gwaed Cymru yn croesawu’r penderfyniad i gael gwared yn ddiogel â’r gwaharddiad ar ddefnyddio plasma o’r DU i gynhyrchu meddyginiaeth.  
> 
> “Mae’r rhoddion gwaed cyfan yr ydym yn eu cael eisoes yn helpu i ddarparu plasma clinigol ar gyfer triniaethau penodol, megis cefnogi cleifion sydd ag anafiadau llosgi.  
> 
>   
> 
> “Mae gwaith pellach i’w wneud, ond bydd ein gwasanaeth nawr yn ystyried gyda Llywodraeth Cymru beth yw’r ffordd orau inni fanteisio ar y cyfle hwn er lles pobl Cymru.”







Translation:


 
The lifting of the ban follows a review by the Commission on Human Medicine (CHM) and the Medicines and Healthcare products Regulatory Agency (MHRA).


It was introduced in the UK in 1999 in response to the variant Creutzfeld–Jakob (vCJD) epidemic, believed to be associated with the consumption of meat products infected with BSE, commonly known as "mad cow disease".


Since the introduction of the ban, plasma\-derived medicinal products have had to be imported, with the main source at present being the USA.


Health Minister Vaughan Gething said:



> “The need to import plasma into the UK has meant NHS Wales has had to prioritise supply of medicines to patients with the highest clinical need.
> 
> 
> “The pandemic is placing further pressures on this supply due to the increased need for blood plasma in the development of new Covid\-19 medicines coupled with the falling numbers of blood plasma donations.
> 
> 
> “Following multiple reviews of the evidence, we have been advised that plasma sourced in the UK is safe for the manufacture of these medicines and as such, I along with the other health ministers across the UK have lifted the ban to potentially save their lives and help people to manage their conditions.”


Director of the Welsh Blood Service, Alan Prosser, said:



> “The Welsh Blood Service welcomes the decision to safely end the ban on using UK plasma to manufacture medicines.
> 
> 
> “The whole blood donations we receive already help provide clinical plasma for specific treatments, such as supporting patients with burn injuries.
> 
> 
> “There is further work to do, but our service will now explore with Welsh Government how we can best maximise this opportunity for the population of Wales.”